Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis
As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. 300 mg of canagliflozin was the best option among the included interventions considering favourable glucose control and WL. Some novel SGLT2is (eg, henagliflozin) exhibited promising efficacy and safety profiles, but more research is needed to validate the findings.
Authors
- Guo Ma (ORCID: https://orcid.org/0000-0001-5524-7172)
- Yike Wu (ORCID: https://orcid.org/0000-0002-4471-8685)
- Jiyifan Li
- Longzhou Li
- Tingting Gong (ORCID: https://orcid.org/0009-0006-7909-7811)
- Junwei Chow
- Lei Xu (ORCID: https://orcid.org/0000-0001-7648-8100)
- Zihan Wang (ORCID: https://orcid.org/0000-0001-8193-7054)
- Ting Li (ORCID: https://orcid.org/0000-0001-5145-3024)
- Yanan Ding (ORCID: https://orcid.org/0000-0002-8742-0926)
- Haiyang Liu (ORCID: https://orcid.org/0000-0001-6332-6751)
Institutions
- Fudan University (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-088687
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- National Natural Science Foundation of China